Arginase inhibitors and methods of use

US11274111B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Abdelghani Achab · Melrose, US
• Jared N. Cumming · Garwood, US
• Christian Fischer · Natick, US
• Symon Gathiaka · Waltham, US
• Charles A. Lesburg · Newton, US
• Derun Li · Dedham, US
• Min Lu · San Diego, US
• Matthew J. Mitcheltree · Cambridge, US
• Anandan Palani · Bound Brook, US
• Rachel L. Palte · Melrose, US
• David L. Sloman · Brookline, US
• Hongjun Zhang · Waterloo, CA

Key dates

• Filing date: Jun 14, 2019
• Grant date: Mar 15, 2022
• Expiry date: Jun 14, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K16/2818
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Described herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. The compounds of Formula (I) act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.